Pathologists actively participate in colorectal cancer multidisciplinary team

doi:10.3877/cma.j.issn.2095-3224.2016.04.006

Abstract

Abstract:

Multidisciplinary team (MDT) is an effective treatment worldwide for tumor patients, including that of colorectal cancer. Pathologists, as core members of the MDT, actively participate in the regular meeting, which can optimize our routine works and increase our professional level. During ten years of clinic practice of the MDT, the pathologists not only provide accurate diagnoses for the patients but also increase themselves′ diagnostic and research level. According to our precise diagnosis report, the clinicians make a personalized treatment for the colorectal cancer patient. So we think the MDT mode is worthy to be popularized among oncologic workers.

Key words: Colorectal neoplasms, Pathology, clinical, multidisciplinary team

Qiongrong Chen, Shaozhong Wei. Pathologists actively participate in colorectal cancer multidisciplinary team[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(04): 309-314.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.04.006

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I04/309

Figures/Tables 1

References 33

[1]	Grass C, Umansky R. Problems in promoting the growth of multi-disciplinary diagnostic and counseling clinics for mentally retarded children in nonmetropolitan areas[J]. Am J Public Health, 1971, 61(4):698-710.
[2]	Poulton BC, West MA. Effective multidisciplinary teamwork in primary health care[J]. J Adv Nurs, 1993, 18(6):918-925.
[3]	王哲，王瑞安. 译. 外科病理取材图解指南, 第二版[M]. 西安：第四军医大学出版社, 2009: 70-75.
[4]	Edge SB, Byrd SR, Compton CC, et al. AJCC Cancer Staging Manual, 7th edition[M]. New York: Springer-Verlag, 2010: 143-164.
[5]	杨凯，侯远发，宋耀明, 等. 直肠癌新辅助治疗后手术标本的淋巴结检出[J]. 中国实用医药, 2014,(11):79-80.
[6]	顾晋，王林. 中低位直肠癌环周切缘的规范化检测及研究进展[J]. 中华胃肠外科杂志, 2011, 14(4):229-233.
[7]	王林，顾晋. 结直肠癌的规范化病理诊断要点[J]. 中华胃肠外科杂志, 2012, 15(10):1088-1091.
[8]	叶颖江，申占龙，王杉. 结直肠癌多学科专家组诊疗模式[J]. 医学与哲学, 2010, 31(3):14-16.
[9]	蔡三军. 结直肠癌的规范性多学科治疗[J]. 中华胃肠外科杂志, 2010, 13(4):245-246.
[10]	中华医学会消化内镜学分会病理学协作组. 中国消化内镜活组织检查与病理学检查规范专家共识（草案）[J]. 中华消化内镜杂志, 2014, 31(9):481-548.
[11]	陈光勇，黄受方，石晓燕, 等. 内镜下胃黏膜切除标本病理学规范化检查的建议[J]. 中华病理学杂志, 2014, 43(5):344-347.
[12]	刘鹏军，葛亚强，王晓燕, 等. 内镜下黏膜下层剥离术治疗上消化道黏膜高级别上皮内瘤变的价值及术后病理分析[J]. 胃肠病学和肝病学杂志, 2015, 24(12):1433-1436.
[13]	Haggitt RC, Glotzbach RE, Soffer EE, et al. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy[J]. Gastroenterology, 1985, 89(2):328-336.
[14]	Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited[J]. Gut, 2002, 51(1):130-131.
[15]	Kazama S, Watanabe T, Ajioka Y, et al. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2[J]. Br J Cancer, 2006, 94(2):293-298.
[16]	Ruzzo A, Graziano F, Canestrari E, et al. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients[J]. Curr Cancer Drug Targets, 2010, 10(1):68-79.
[17]	Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015[J]. J Clin Oncol, 2016, 34(2):179-185.
[18]	Niessen RC, Berends MJ, Wu Y, et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer[J]. Gut, 2006, 55(12):1781-1788.
[19]	Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer（Lynch syndrome) and microsatellite instability[J]. J Natl Cancer Inst, 2004, 96(4):261-268.
[20]	Jenkins MA, Hayashi S, O′Shea AM, et al. Pathology Features in Bethesda Guidelines Predict Colorectal Cancer Microsatellite Instability: A Population-Based Study[J]. Gastroenterology, 2007, 133(1):48-56.
[21]	Guastadisegni C, Colafranceschi M, Ottini L, et al. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data[J]. Eur J Cancer, 2010, 46(15):2788-2798.
[22]	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[J]. N Engl J Med, 2015, 372(26):2509-2520.
[23]	Hamilton SR, Bosman FT, Boffetta P, et al. In: Carneiro F, Hruban RH, et al, eds. World Health Organization Tumours. WHO Classification of Tumours of the Digestive System[M]. Lyon: IARC Press, 2010: 134-177.
[24]	Ueno H, Kajiwara Y, Shimazaki HS, et al. New criteria for histologic grading of colorectal cancer[J]. Am J Surg Pathol, 2012, 36(2):193-201.
[25]	Barresi V, Reggiani Bonetti L, Branca G, et al. Colorectal carcinoma grading by quantifying poorly differentiated cell clusters is more reproducible and provides more robust prognostic information than conventional grading[J]. Virchows Arch, 2012, 461(6):621-628.
[26]	Rosty C, Williamson EJ, Clendenning M, et al. Should the grading of colorectal adenocarcinoma include microsatellite instability status?[J]. Hum Pathol, 2014, 45(10):2077-2084.
[27]	Barresi V, Bonetti LR. Correlation between microsatellite instability status and grading assessed by the counting of poorly differentiated clusters in colorectal cancer[J]. Hum Pathol, 2015, 46(7):1063.
[28]	Alcantara SB, Reed W, Willis K, et al. Radiologist participation in multi-disciplinary teams in breast cancer improves reflective practice, decision making and isolation[J]. Eur J Cancer Care（Engl), 2014, 23(5):616-623.
[29]	Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer[J]. Arch Gynecol Obstet, 2014, 290(5):839-842.
[30]	McCluggage WG, Judge MJ, Clarke BA, et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting（ICCR) [J]. Mod Pathol, 2015, 28(8):1101-1122.
[31]	Moss EL, Evans T, Pearmain P, et al. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma[J]? Int J Gynecol Cancer, 2015, 25(7):1201-1207.
[32]	Nik NN, Vang R, Shih IeM, et al. Origin and pathogenesis of pelvic（ovarian, tubal, and primary peritoneal) serous carcinoma[J]. Annu Rev Pathol, 2014, 9:27-45.
[33]	Herzog TJ, Monk BJ, Rose PG, et al. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum and fallopian tube[J]. Gynecol Oncol, 2014, 132(3):517-525.

Please choose a citation manager

Content to export